Eiger BioPharmaceuticals Stock Forecast, Price & News

Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

Is Eiger BioPharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eiger BioPharmaceuticals stock.
View analyst ratings for Eiger BioPharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Eiger BioPharmaceuticals.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.03.
View Eiger BioPharmaceuticals' earnings history.

How has Eiger BioPharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EIGR shares have increased by 6.5% and is now trading at $7.25.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for EIGR?

4 brokerages have issued 1-year price objectives for Eiger BioPharmaceuticals' shares. Their forecasts range from $22.00 to $45.00. On average, they expect Eiger BioPharmaceuticals' share price to reach $30.50 in the next year. This suggests a possible upside of 320.7% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:

• David A. Cory, President, Chief Executive Officer & Director
• Sriram Ryali, Chief Financial Officer
• Ingrid C. Choong, Senior Vice President-Clinical Development
• Colin Hislop, Senior VP-Clinical & Development Operations
• Chris Dadas, Vice President-Medical Affairs

Who are some of Eiger BioPharmaceuticals' key competitors?

Some companies that are related to Eiger BioPharmaceuticals include Graphite Bio (GRPH), iTeos Therapeutics (ITOS), Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), Omega Therapeutics (OMGA), Immatics (IMTX), Mesoblast (MESO), Tenaya Therapeutics (TNYA), Taysha Gene Therapies (TSHA), Curis (CRIS), Precision BioSciences (DTIL), Finch Therapeutics Group (FNCH), Aligos Therapeutics (ALGS), Osiris Therapeutics (OSIR) and Talaris Therapeutics (TALS).
View all of EIGR's competitors.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (8.69%), BlackRock Inc. (7.29%), Vanguard Group Inc. (4.96%), Geode Capital Management LLC (1.76%), State Street Corp (1.60%) and Goldman Sachs Group Inc. (1.22%). Company insiders that own Eiger BioPharmaceuticals stock include Eldon C Mayer III, Evan Loh, Jeffrey S Glenn and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals.

Which institutional investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Susquehanna International Group LLP, Russell Investments Group Ltd., BlackRock Inc., Northern Trust Corp, and Citadel Advisors LLC. Company insiders that have sold Eiger BioPharmaceuticals company stock in the last year include Eldon C Mayer III, and Evan Loh.
View insider buying and selling activity for Eiger BioPharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Bridgeway Capital Management LLC, Morgan Stanley, Morgan Stanley, Vanguard Group Inc., GSA Capital Partners LLP, Caxton Corp, and Geode Capital Management LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include Eldon C Mayer III, Jeffrey S Glenn, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $7.25.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals has a market capitalization of $246.14 million. The biotechnology company earns $-65,050,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Eiger BioPharmaceuticals have?

Eiger BioPharmaceuticals employs 28 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

Where are Eiger BioPharmaceuticals' headquarters?

Eiger BioPharmaceuticals is headquartered at 2155 PARK BOULEVARD, PALO ALTO CA, 94306.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at (650) 272-6138 or via email at [email protected].